Modulation of Stress and Immune Response by Amblyomin-X Results in Tumor Cell Death in a Horse Melanoma Model

We have investigated Amblyomin-X-treated horse melanomas to better understand its mode of action through transcriptome analysis and the in vivo model. Amblyomin-X is a Kunitz-type homologous protein that selectively leads to the death of tumor cells via ER stress and apoptosis, currently under investigation as a new drug candidate for cancer treatment. Melanomas are immunogenic tumors, and a better understanding of the immune responses is warranted. Equine melanomas are spontaneous and not so aggressive as human melanomas are, as this study shows that the in vivo treatment of encapsulated horse melanoma tumors led to a significant reduction in the tumor size or even the complete disappearance of the tumor mass through intratumoral injections of Amblyomin-X. Transcriptome analysis identified ER- and mitochondria-stress, modulation of the innate immune system, apoptosis, and possibly immunogenic cell death activation. Interactome analysis showed that Amblyomin-X potentially interacts with key elements found in transcriptomics. Taken together, Amblyomin-X modulated the tumor immune microenvironment in different ways, at least contributing to induce tumor cell death.

Citing Articles

A glimpse into the world of microRNAs and their putative roles in hard ticks.

Leal-Galvan B, Kumar D, Karim S, Saelao P, Thomas D, Oliva Chavez A Front Cell Dev Biol. 2024; 12:1460705.

PMID: 39376631 PMC: 11456543. DOI: 10.3389/fcell.2024.1460705.

Programmed Cell Death-Ligand 1 (PD-L1) Immunohistochemical Expression in Equine Melanocytic Tumors.

Pimenta J, Prada J, Pires I, Cotovio M Animals (Basel). 2024; 14(1).

PMID: 38200779 PMC: 10778310. DOI: 10.3390/ani14010048.

First Proteome Analysis of Poplar-Type Propolis.

Suran J, Radic B, Trevisan-Silva D, Cindric M, Hozic A Plant Foods Hum Nutr. 2023; 79(1):83-89.

PMID: 38048032 DOI: 10.1007/s11130-023-01127-w.

Structural and functional properties of the Kunitz-type and C-terminal domains of Amblyomin-X supporting its antitumor activity.

Morais K, Ciccone L, Stura E, Alvarez-Flores M, Mourier G, Driessche M Front Mol Biosci. 2023; 10:1072751.

PMID: 36845546 PMC: 9948614. DOI: 10.3389/fmolb.2023.1072751.

Equine Melanocytic Tumors: A Narrative Review.

Pimenta J, Prada J, Cotovio M Animals (Basel). 2023; 13(2).

PMID: 36670786 PMC: 9855132. DOI: 10.3390/ani13020247.

References

Smith S, Goldschmidt M, McManus P . A comparative review of melanocytic neoplasms. Vet Pathol. 2002; 39(6):651-78. DOI: 10.1354/vp.39-6-651. View

Hodis E, Watson I, Kryukov G, Arold S, Imielinski M, Theurillat J . A landscape of driver mutations in melanoma. Cell. 2012; 150(2):251-63. PMC: 3600117. DOI: 10.1016/j.cell.2012.06.024. View

Zhao Z, Duffy D, Thomas S, Martin N, Hayward N, Montgomery G . Polymorphisms in the syntaxin 17 gene are not associated with human cutaneous malignant melanoma. Melanoma Res. 2009; 19(2):80-6. PMC: 3665505. DOI: 10.1097/CMR.0b013e328322fc45. View

Pielberg G, Golovko A, Sundstrom E, Curik I, Lennartsson J, Seltenhammer M . A cis-acting regulatory mutation causes premature hair graying and susceptibility to melanoma in the horse. Nat Genet. 2008; 40(8):1004-9. DOI: 10.1038/ng.185. View

van der Weyden L, Patton E, Wood G, Foote A, Brenn T, Arends M . Cross-species models of human melanoma. J Pathol. 2015; 238(2):152-65. PMC: 4832391. DOI: 10.1002/path.4632. View

Batista I, Chudzinski-Tavassi A, Faria F, Simons S, Barros-Batestti D, Labruna M . Expressed sequence tags (ESTs) from the salivary glands of the tick Amblyomma cajennense (Acari: Ixodidae). Toxicon. 2008; 51(5):823-34. DOI: 10.1016/j.toxicon.2007.12.011. View

Branco V, Iqbal A, Alvarez-Flores M, Sciani J, De Andrade S, Iwai L . Amblyomin-X having a Kunitz-type homologous domain, is a noncompetitive inhibitor of FXa and induces anticoagulation in vitro and in vivo. Biochim Biophys Acta. 2016; 1864(10):1428-35. DOI: 10.1016/j.bbapap.2016.07.011. View

Maria D, de Souza J, Morais K, Berra C, Zampolli H, Demasi M . A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production. Invest New Drugs. 2012; 31(3):493-505. PMC: 3644403. DOI: 10.1007/s10637-012-9871-1. View

Chudzinski-Tavassi A, Morais K, Pacheco M, Pasqualoto K, de Souza J . Tick salivary gland as potential natural source for the discovery of promising antitumor drug candidates. Biomed Pharmacother. 2016; 77:14-9. DOI: 10.1016/j.biopha.2015.11.003. View

10.

Morais K, Pacheco M, Berra C, Bosch R, Sciani J, Chammas R . Amblyomin-X induces ER stress, mitochondrial dysfunction, and caspase activation in human melanoma and pancreatic tumor cell. Mol Cell Biochem. 2016; 415(1-2):119-31. PMC: 4819916. DOI: 10.1007/s11010-016-2683-4. View

11.

Chudzinski-Tavassi A, De-Sa-Junior P, Simons S, Maria D, Ventura J, Correia Batista I . A new tick Kunitz type inhibitor, Amblyomin-X, induces tumor cell death by modulating genes related to the cell cycle and targeting the ubiquitin-proteasome system. Toxicon. 2010; 56(7):1145-54. DOI: 10.1016/j.toxicon.2010.04.019. View

12.

Akagi E, Junior P, Simons S, Bellini M, Barreto S, Chudzinski-Tavassi A . Pro-apoptotic effects of Amblyomin-X in murine renal cell carcinoma "in vitro". Biomed Pharmacother. 2012; 66(1):64-9. DOI: 10.1016/j.biopha.2011.11.015. View

13.

Zanotto-Filho A, Braganhol E, Battastini A, Moreira J . Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling. Invest New Drugs. 2012; 30(6):2252-62. DOI: 10.1007/s10637-012-9804-z. View

14.

Mehta-Shah N, Younes A . Novel targeted therapies in diffuse large B-cell lymphoma. Semin Hematol. 2015; 52(2):126-37. DOI: 10.1053/j.seminhematol.2015.01.007. View

15.

Honma Y, Shimizu S, Takehara T, Harada M . Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases. J Gastroenterol. 2013; 49(3):517-26. DOI: 10.1007/s00535-013-0796-z. View

16.

Laporte A, Barrott J, Yao R, Poulin N, Brodin B, Jones K . HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma. PLoS One. 2017; 12(1):e0169407. PMC: 5215898. DOI: 10.1371/journal.pone.0169407. View

17.

Fernandez Y, Verhaegen M, Miller T, Rush J, Steiner P, Opipari Jr A . Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res. 2005; 65(14):6294-304. DOI: 10.1158/0008-5472.CAN-05-0686. View

18.

Sorolla A, Yeramian A, Dolcet X, Perez de Santos A, Llobet D, Schoenenberger J . Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines. Br J Dermatol. 2008; 158(3):496-504. DOI: 10.1111/j.1365-2133.2007.08390.x. View

19.

Reuland S, Goldstein N, Partyka K, Smith S, Luo Y, Fujita M . ABT-737 synergizes with Bortezomib to kill melanoma cells. Biol Open. 2012; 1(2):92-100. PMC: 3507205. DOI: 10.1242/bio.2011035. View

20.

Selimovic D, Porzig B, El-Khattouti A, Badura H, Ahmad M, Ghanjati F . Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells. Cell Signal. 2012; 25(1):308-18. DOI: 10.1016/j.cellsig.2012.10.004. View